Helsinki University Central Hospital
- Address
- Haartmaninkatu 4, 00290 Helsinki, Finland
Cardiovascular Diseases
At Helsinki University Central Hospital the Heart and Lung Center concentrates on coronary artery disease, seeking to advance interventional care for patients with elevated bleeding risk.
- Evaluation of drug‑coated balloon therapy
- Comparison with drug‑eluting stents
- Shortened dual‑antiplatelet therapy regimens
- Strategies for high bleeding risk populations
Ongoing studies aim to demonstrate that a drug‑coated balloon approach combined with reduced dual‑antiplatelet therapy can be as effective as traditional drug‑eluting stents, offering safer options for those prone to bleeding.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 26 therapeutic areas and 15 of 477 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 435 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 99 by active trials.
- 1HUS-yhtymae26active
lock +98 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1HUS-yhtymae31trials
lock +53 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helsinki University Central Hospital
lock Showing 1 of 317 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 477 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 22 | Unknown | 2015-05-05 | 2025-12-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.